HIV-V-A002 (MENSCH)
Status:Completed
Phase:I
Principal Investigator(s):Crucell Holland BV
Objective:The purpose of this study is to assess the safety and tolerability of Modified Vaccinia Ankara (MVA) Mosaic vaccine in healthy adult participants.
Prevention Option(s):HIV Vaccine
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionHealthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
Mode of Delivery
ARMsExperimental
DescriptionHealthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
Mode of Delivery
ARMsExperimental
DescriptionHealthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
Mode of Delivery
ARMsExperimental
DescriptionParticipants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
Mode of Delivery
ARMsExperimental
Official Code:
NCT02218125
Trial Sponsors:
Beth Israel Deaconess Medical Center, Crucell Holland BV, NIAID, US Military HIV Research Program
Start Date
End Date
September 1, 2014
November 1, 2015
Enrollment:25
Age range:
18 Years ↔
55 Years
Population:Cisgender Men, Cisgender Women